UNDERWRITING AGREEMENTUnderwriting Agreement • June 23rd, 2022 • Shuttle Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • California
The undersigned, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) with Boustead Securities, LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
ContractShuttle Pharmaceuticals Holdings, Inc. • June 23rd, 2022 • Pharmaceutical preparations • California
THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING [●], 2022 (THE “EFFECTIVE DATE”) TO ANYONE OTHER THAN (I) BOUSTEAD SECURITIES, LLC OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING FOR WHICH THIS PURCHASE WARRANT WAS ISSUED TO THE UNDERWRITER AS CONSIDERATION (THE “OFFERING”), OR (II) AN OFFICER, PARTNER, REGISTERED PERSON OR AFFILIATE OF BOUSTEAD SECURITIES, LLC.
EMPLOYMENT AGREEMENTEmployment Agreement • June 23rd, 2022 • Shuttle Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • Maryland
This Employment Agreement (the “Agreement”) is entered into as of the 28th day of June, 2019, by and between Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and Anatoly Dritschilo, M.D., an individual residing at the address set forth on Schedule A hereto (the “Executive”).
SUBLICENSE AGREEMENTSublicense Agreement • June 23rd, 2022 • Shuttle Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • Maryland
This SUBLICENSE AGREEMENT (the “Agreement”), effective as of the last date of signature below (the “Effective Date”), is entered into by and between PROPAGENIX Inc., a Delaware corporation having a main office at 9605 Medical Center Drive, Suite 325, Rockville, MD, 20850, United States (“PROPAGENIX”) and Shuttle Pharmaceuticals, Inc. (“SHUTTLE”), a pharmaceutical corporation having its offices at One Research Court, Suite 450, Rockville, MD 20850. PROPAGENIX and SHUTTLE may be referred to herein individually as a “Party” and collectively as the “Parties.”
Shuttle Pharmaceuticals, Inc.Materials Transfer Agreement • June 23rd, 2022 • Shuttle Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations
This Material Transfer Agreement (“Agreement”) is hereby made by and between the GeorgeWashington University (hereinafter “Recipient”) and Shuttle Pharmaceuticals, Inc, Rockville, MD (hereinafter “Provider”) upon request from Recipient for the following material (hereinafter “Material”) more particularly described below:
Subaward AgreementSubaward Agreement • June 23rd, 2022 • Shuttle Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations
Estimated Cost($) Fixed Fee($) Estimated Cost Plus Fixed Fee($)Beginning • June 23rd, 2022 • Shuttle Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations
If the Government exercises its option for Phase II pursuant to the Option Provision Article in Section H of this contract, the total estimated Subcontract amount will be increased as follows:
